Market closedNon-fractional
PDS Biotechnology/PDSB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About PDS Biotechnology
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Ticker
PDSB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Princeton, United States
Employees
25
Website
www.pdsbiotech.com
PDSB Metrics
BasicAdvanced
$114M
Market cap
-
P/E ratio
-$1.37
EPS
1.75
Beta
-
Dividend rate
Price and volume
Market cap
$114M
Beta
1.75
Financial strength
Current ratio
4.56
Quick ratio
4.424
Long term debt to equity
45.073
Total debt to equity
64.837
Interest coverage (TTM)
-9.91%
Management effectiveness
Return on assets (TTM)
-39.76%
Return on equity (TTM)
-112.25%
Valuation
Price to book
3.05
Price to tangible book (TTM)
3.05
Price to free cash flow (TTM)
-3.291
Growth
Earnings per share change (TTM)
-3.37%
3-year earnings per share growth
24.51%
What the Analysts think about PDSB
Analyst Ratings
Majority rating from 6 analysts.
PDSB Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
-1.85%
Profit margin
0.00%
NaN%
PDSB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
-$0.35
-$0.35
-$0.30
-
Expected
-$0.35
-$0.45
-$0.44
-$0.37
-$0.34
Surprise
6.58%
-21.47%
-20.20%
-18.18%
-
PDSB News
AllArticlesVideos
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
GlobeNewsWire·2 months ago
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PDS Biotechnology stock?
PDS Biotechnology (PDSB) has a market cap of $114M as of July 06, 2024.
What is the P/E ratio for PDS Biotechnology stock?
The price to earnings (P/E) ratio for PDS Biotechnology (PDSB) stock is 0 as of July 06, 2024.
Does PDS Biotechnology stock pay dividends?
No, PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next PDS Biotechnology dividend payment date?
PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders.
What is the beta indicator for PDS Biotechnology?
PDS Biotechnology (PDSB) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell PDS Biotechnology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.